Zobrazeno 1 - 10
of 369
pro vyhledávání: ''
Autor:
Julie Means-Powell, Luis Del Valle, Vandana G. Abramson, Claudia Sorrentino, Melinda Sanders, Ingrid A. Mayer, Debra A. Tonetti, Roohi Ismail-Khan, Samarpan Majumder, Richard M Lush, Lucio Miele
Publikováno v:
Clin Breast Cancer
Preclinical studies have demonstrated a complex cross-talk between Notch and estrogen signaling in ERα-positive breast cancer. Gamma-secretase inhibitors (GSIs) are investigational agents that block the cleavage and activation of Notch receptors. In
Autor:
Xiaoling Xuei, J. Julie Kim, Minhua Wang, Oukseub Lee, Susan E. Clare, Seema A. Khan, Priyam Patel, Omid Hosseini, Matthew J. Schipma, Maarten C. Bosland, Irene Helenowski, Ali Shidfar
Publikováno v:
Cancer Letters. 520:255-266
Pharmacological approaches to breast cancer risk-reduction for BRCA1 mutation carriers would provide an alternative to mastectomy. BRCA1-deficiency dysregulates progesterone signaling, promoting tumorigenesis. Selective progesterone receptor (PR) mod
Autor:
Timothy F. Burns, Patrick J. Ward, D. Ross Camidge, Martina M. Koch, Carrianne Ludwig, Christine L. Hann, Maulik Patel, Afshin Dowlati, Daniel Morgensztern, Chris Chen, Halla Nimeiri, Philip Komarnitsky
Publikováno v:
Journal of Thoracic Oncology. 16:1582-1588
Introduction Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting DLL3, a Notch pathway ligand highly expressed on SCLC cells. Rova-T was evaluated alone or in combination with platinum-based chemotherapy (cisplatin or carboplatin
Autor:
Jianying Zhou, Xiusong Qiu, Wangjun Liao, Yanping Hu, Jie Wang, Zhehai Wang, Mengzhao Wang, Yan Yu, Zhiyong Ma, Yuanyuan Bao, Dong Wang, Jiuwei Cui, Shun Lu, Yuping Sun, Xinghao Ai, Jie Gao, Liang Liang, Wu Zhuang, Xinmin Yu, Yunpeng Liu, Xingya Li, Weidong Li
Publikováno v:
Journal of Thoracic Oncology. 16:1512-1522
Introduction Tislelizumab, an anti–programmed cell death protein-1 antibody, was specifically engineered to minimize FcɣR macrophage binding to abrogate antibody-dependent phagocytosis. Compared with chemotherapy alone, tislelizumab plus chemother
Autor:
Laetitia Dahan, Romain Cohen, Meher Ben Abdelghani, Hélène Castanié, Christophe Tournigand, Jean-Philippe Metges, Paul Gougis, Anthony Turpin, Cindy Neuzillet, Jean-Frédéric Blanc, Dewi Vernerey, David Tougeron, Benoit Rousseau, Marc Hilmi, Marie-Line Garcia-Larnicol, Alice Boilève
Publikováno v:
European Journal of Cancer. 143:55-63
Background The IMMUNOBIL PRODIGE 57 trial is a non-comparative randomized phase II study assessing the efficacy and safety of the durvalumab (an anti-PD-L1) and tremelimumab (an anti-CTLA4) combination with or without weekly paclitaxel in patients wi
Publikováno v:
Clinical Genitourinary Cancer. 18:416-422
Background Numerous globally approved castration-resistant prostate cancer (CRPC) therapies are available. Enzalutamide and radium 223 (Ra 223) are approved for survival prolongation and ability to delay radiographic progression. Both have markedly d
Autor:
Yongsheng Wang, Di-Yuan Qin, Youling Gong, Fuchun Guo, Li Xiang, Xiaoyu Li, Xiaoke Liu, Yuhong Ou, Li Jiang, Qing Qin, Zeming Mo, Pei Shu, Dan Li, Xin Wang
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 107:804-814
Purpose To determine the role of NLRP3 inflammasome activation in low-dose radiation-induced radiation pneumonitis (RP) and to assess whether inhibition or deletion of the NLRP3 inflammasome is critical for conferring protection against RP. Methods a
Publikováno v:
Pediatric Hematology Oncology Journal, Vol 5, Iss 2, Pp 43-47 (2020)
Purpose The purpose of our study was to assess long-term outcomes of patients suffering from retinoblastoma who underwent systemic chemotherapy using vincristine, etoposide, and carboplatin (VEC protocol) followed by other local treatments. Material
Autor:
Ken-ichirou Morishige, Hirotoshi Iihara, Mototsugu Shimokawa, Masakazu Abe, Senri Yamamoto, Takahiro Arai, Yoh Hayasaki, Akio Suzuki, Ryuichi Shimaoka, Kazuto Nakamura, Minako Mori, Saki Murase, Motoki Takenaka, Nobuhiro Kado, Michiru Sakurai, Yukiyoshi Fujita
Publikováno v:
Gynecologic Oncology. 156:629-635
Purpose The aim of this study was to investigate the efficacy and safety of prophylactic administration of 5 mg olanzapine (OLZ) combined with neurokinin 1 receptor antagonist (NK1RA), 5-hydroxytryptamine type-3 receptor antagonist (5-HT3RA), and dex
Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer
Autor:
Hiroko Yano, Shoji Nagao, Kazuko Matsuoka, Satoshi Yamaguchi, Takaya Shiozaki, Kazuhiro Suzuki, Takashi Shibutani, Kasumi Yamamoto, Miho Kitai, Tomoatsu Jimi
Publikováno v:
Gynecologic Oncology. 154:554-557
Objective We evaluated the efficacy and safety of the combination of paclitaxel, carboplatin, and bevacizumab in patients with advanced or recurrent cervical cancer. Methods Subjects included patients with advanced or recurrent cervical cancer not am